Lavie, D. Et Al. 2024. Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA .

Lavie, D., ÖZCAN, M., Chaudhry, A., Zhou, X., Paydar, I., Farooqui, M. Z. H., ... Ghia, P.(2024). Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA .

Lavie, David Et Al. "Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)," CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2024

Lavie, David Et Al. "Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2024

Lavie, D. Et Al. (2024) . "Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA .

@article{article, author={David Lavie Et Al. }, title={Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)}, journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA}, year=2024}